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ABSTRACT
Objectives: To assess the overall survival of pregnant women diagnosed with cancer during pregnancy or
became pregnant thereafter.
Methods: A retrospective medical record review of 90 patients who were diagnosed with cancer when
pregnant or who became pregnant thereafter between 1996 and 2015 in Aga Khan University Hospital,
Karachi.
Results: A total of 90 patients were analyzed. The malignancies that expectant mothers had were, breast
cancer 38 (42.2%), hematological cancers 29 (32.2%), brain cancer 10 (11.1%), and other malignancies 13
(14.4%) that included thyroid cancers, gestational trophoblastic disease and synovial tumor of foot. We
observed only four deaths out of 90 patients and mean survival time in pregnant patients with malignancies
was 17.98 years [CI 16.35-19.31].
Conclusions: The diagnosis of most cancer types before or during pregnancy does not influence on overall
survival of patients.
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Cancer is a leading cause of mortality
worldwide, though a rare event during
pregnancy. The annual incidence is reported to
be approximately 1/1,000 pregnancies, which
only makes 0.07% to 0.1% of all malignant
tumors.1 This incidence is expected to increase
due to delay in child bearing age. The common
malignancies noted in pregnant women are
brain, breast cancer, lymphomas, leukemia’s,
cervical and ovarian cancer.2
The pathophysiology of cancer during
pregnancy is poorly understood. Theoretically,
hormonal and immunological variations with an
increase in permeability and vascularization are
thought to affect cancer prognosis and survival.3
Also, the outcomes are dependent on the type
and stage of cancer. Few studies have reported
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a reduced survival rate in this group of women.2
However, there are contradictory findings in
other studies.4,5
According to our knowledge no local data exists
about survival in pregnant women with cancer.
Hence the rationale of this study is to help our
health care providers in the management of these
women and enable them to counsel regarding
prognosis and survival.
METHODS
This was a retrospective observational study
conducted in the department of Obstetrics &
Gynecology, Aga Khan University Hospital
Pakistan (AKUH). Medical records of the patients
diagnosed with cancer during pregnancy and
thereafter from 1996-2015 were reviewed in 2018.
Inclusion criteria included all pregnant women
with histologically confirmed malignant cancer
before and during pregnancy with sufficient
retrievable records code according to ICD-9
codes (International Classification of Diseases,
9th revision) system. The Hospital Information
Management System (HIMS) at AKUH codes
all inpatient medical records for diagnosis
and procedure according (ICD-9-CM) coding
system. Solid cancer Cases coded between 140.0
-195.8, whereas Hematological malignancies were
coded from 2.200.00 to 209.29.
Data was collected on Pre-tested structured
questionnaire after approval from Ethics
Review Committee (ERC) of Aga Khan Hospital.
Medical record files were reviewed for each case.
Patient data comprised of basic demographic
characteristics, obstetric/medical history, cancer
diagnosis on registration, stages and grades of
cancer, treatment administered and outcome.
Data analysis was performed using SPSS version
19. Frequencies (percentages) were estimated for
categorical variables. Overall survival analysis
was conducted by using the Kaplan–Meier
method.
Operational Definition: Overall survival rate:
Overall survival rate is percentage of people
who survive a certain type of cancer for a specific
period of time.6
RESULTS
A total of 120 pregnant women with
malignancies of different sites were registered
at Aga Khan University Hospital between 1998
and 2015. Out of the total, 30 patient’s records
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had incomplete information regarding course
of disease and therefore were excluded from
the study. Five patients were lost to follow up.
Ninety patients were included.
The common malignancies that expectant
mothers had were; breast cancer 38(42.2%),
hematological cancers 29(32.2%), brain tumor
10(11.1%), and other malignancies 13(14.4%)
including
thyroid
cancers,
gestational
trophoblastic disease and synovial tumor of foot.
(Table-I). We observed only 4 deaths out of 90
patients in our study. These deaths were found
in patient with breast cancer and hematological
malignancies.
Most of the patients were more than thirty
years of age i.e. 50 (55.6%), however, majority
women diagnosed with blood cancer patients
were less than thirty years of age i.e., 18 (45%).
More than half of the patients 63(70%) were
multigravida. Approximately, 50% of women
with breast and blood cancers also had history
of more than two miscarriages. (Table-I).
Standard treatment modalities were used in all
women with malignancies. 17 (60.7%) of patients
with breast cancer, 6 (21.4%) of patients with
Table-I: Characteristics of Patients (n=90).
Breast CA Brain CA Hem/Onc Others
38(42.2%) 10(11.1%) 29(32.2%) 13(14.4%)
<30 years
>30 years

Age
10 (25%) 5 (12.5%)
28 (56%) 5 (10%)
Parity
3 (30%)
1 (10%)
31 (49.2%) 6 (9.5%)

Primigravida
Multigravida
(>2)
Grand
4 (23.5%) 3 (17.6%)
multigravida (>5)
Miscarriages
<2
36 (41.9%) 10(11.6%)
>2
2 (50%)
0
Treatment
Surgery
17 (60.7%) 6 (21.4%)
Chemotherapy 21 (38.9%) 4 (7.4%)
Hydroxyurea
0
0
No treatment
0
0
Stage
Stage 1
10 (66.7%) 2 (13.3%)
Stage 2
17 (58.6%) 5 (17.2%)
Stage 3
4 (44.4%) 2 (22.2%)
Stage 4
7 (18.9%) 1 (2.7%)
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18 (45%) 7 (17.5%)
11 (22%) 6 (12%)
3 (30%) 3 (30%)
17 (27%) 9 (14.3%)
9 (52.9%) 1 (5.9%)

27(31.4%) 13(15.1%)
2 (50%)
0
0
5 (17.9%)
23(42.6%) 6 (11.1%)
6 (100%)
0
0
2 (100%)
0
3 (10.3%)
0
26(70.3%)

3 (20%)
4 (13.8%)
3 (33.3%)
3(8.1%)

Pregnancy and cancer survival

Fig.1: Survival analysis.

brain tumor, 5 (17.9%) with other malignancies
had surgery before pregnancy. While, 21 (38.9%)
of breast cancer patients, 4 (7.4%) of patients with
brain tumor, 23 (42.6%) of blood cancer patient,
6 (11.1%) of patients with other malignancies
received chemotherapy.
Most of pregnant patients with blood cancer
were in staged IV i.e. 26 (70.3%). Most frequently
found stage for breast cancer was stage I
infiltrating ductal carcinoma i.e. 10 (66.7%). As
shown in survival curve (Fig.1) mean survival
time in the patients with malignancies was found
to be 17.98 years [CI 16.35-19.31].
DISCUSSION
The present study was performed to determine
the common cancer types in pregnant women
in our population and their characteristics
and the effect of pregnancy on cancer survival
in our setting. The cancer types which were
commonly observed in our cohort were breast
cancer, leukemias, lymphomas and brain tumors,
consistent with the results of Palvidis et al.7
Till 2018 the cumulative survival time in our
subjects was found to be 17.98 years. Which is
consistent with one nationwide, registry-based
study on most frequent cancer diagnoses during
pregnancy and lactation. This confirms diagnosis
of cancer during pregnancy or lactation does
not increase the risk of cause-specific death
compared with control group.
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The most frequent tumor seen in these women
was breast cancer. Majority of them were
diagnosed during pregnancy. The reason might
be as they have their first examination from a
healthcare provider during pregnancy and thus
are diagnosed late, which is contrary to the
data from developed countries where national
screening program are well established.8 In our
patients with breast cancer, the most common
type was Infiltrating Ductal Carcinoma (IDC),
diagnosed at Stages I and II. Most of these
patients received chemotherapy during second
and third trimester whereas seventeen (60.7%)
patients were planned to have breast cancer
surgery at the time of cesarean section. Overall
survival of this group showed healthy mother
effect and these results are consistent with Iqbal
J et al study that showed pregnancy did not
adversely affect survival in women with breast
cancer.9
In our study, hematological malignancies
observed were leukemia, lymphomas and
essential
thrombocytosis.
Due
to
some
incomplete information, the effect of histological
type and stage could not be assessed on overall
survival rate of these patients. We had twenty
nine women in this group, out of which nineteen
cases were diagnosed before pregnancy and ten
during pregnancy. Among these patients, twenty
three (42.6%) received chemotherapy and six
(100%) cases of essential thrombocytosis received
hydroxyurea before pregnancy. From this group
of patients, three women underwent termination
of pregnancy as the chemotherapy was planned
to start in the first trimester of pregnancy. Our
findings suggest that prognosis of hematological
malignancies during pregnancy is comparable
to non-pregnant women, and usually good for
those who received chemotherapy in the second
half of pregnancy. This is in agreement with
Hossam K et al findings.10 That also embarked
upon the importance of gestational age at
diagnosis, stage of malignancy and teratogenicity
of chemotherapeutic agent during pregnancy, if
chemotherapy is necessary during first trimester
then termination of pregnancy is generally
indicated, But the outcome is usually good for
those patients who receive chemotherapy in the
second or third trimester.
The third most common cancer in our study
was glial tumor of brain. It included, five patients
with Grade-II astrocytoma, three had Grade-II
and III oligodendroglioma and two had Grade-II
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ependymoma. Majority of them had post cancer
pregnancies except two who were diagnosed
during pregnancy with Grade-II astrocytoma and
Grade-II oligodendroglioma, respectively. Out
of total, six (21.4%) patients underwent surgery
before pregnancy and four (7.4%) patients
received chemotherapy. None of the patients had
disease progression during pregnancy; which is
consistent with Rønning PA study, that showed
pregnancy have no impact on the survival of
patients with Low grade gliomas.11
Other tumors included gestational trophoblastic
disease, thyroid cancers and synovial foot tumor, all
these pregnancies occurred after the treatment of the
cancer. Similar to other studies regarding thyroid
cancer and gestational trophoblastic diseases,12,13
we did not found statistically significant difference
in overall survival for pregnant women.
There were four mortalities in our cohort. Two
of these patients died of advanced stage breast
cancer (stage IV and Stage III IDC, respectively).
Both of these patients had full term deliveries
with mean survival time of two years. The third
mortality was of patient with Stage IV IDC who
underwent termination of pregnancy at six weeks
and survived for one year. This leads to belief
that the extent of the disease at diagnosis has an
impact on survival. Fourth case was in a woman
with acute myeloid leukemia diagnosed in second
trimester of pregnancy and delivered at term. She
died after sixteen years due to sepsis.
The strength of our study is the compliance of
our patients for long term follow up. The reason
for this could be as the study was conducted in a
private, fully-equipped, centrally-located, tertiary
care hospital, also catering patients referred from
remote areas.
Limitations of the study: It includes limited number
of patients and its retrospective nature. In a few
cases the information was missing about certain
details related to extent and course of the disease.
However, it was not associated with significant
impact on the overall survival analysis of these
patients.
CONCLUSIONS
The diagnosis of most cancer types before or
during pregnancy has no influence on overall
survival of patients.
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